四环生物
(000518)
| 流通市值：21.41亿 | | | 总市值：21.41亿 |
| 流通股本：10.30亿 | | | 总股本：10.30亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 179,935,611.58 | 121,411,354.73 | 57,013,482.58 | 270,149,197.6 |
| 营业收入 | 179,935,611.58 | 121,411,354.73 | 57,013,482.58 | 270,149,197.6 |
| 利息收入 | 0 | 0 | 0 | - |
| 已赚保费 | 0 | 0 | 0 | - |
| 手续费及佣金收入 | 0 | 0 | 0 | - |
| 二、营业总成本 | 215,754,291.95 | 152,287,243.47 | 74,401,151.38 | 311,217,662.78 |
| 营业成本 | 52,199,779.86 | 34,983,170.56 | 18,072,240.23 | 78,248,744.29 |
| 利息支出 | 0 | 0 | 0 | - |
| 手续费及佣金支出 | 0 | 0 | 0 | - |
| 退保金 | 0 | 0 | 0 | - |
| 赔付支出净额 | 0 | 0 | 0 | - |
| 提取保险合同准备金净额 | 0 | 0 | 0 | - |
| 保单红利支出 | 0 | 0 | 0 | - |
| 分保费用 | 0 | 0 | 0 | - |
| 税金及附加 | 1,363,136.33 | 873,314.05 | 273,305.1 | 2,082,398.16 |
| 销售费用 | 90,286,488.06 | 65,807,996.66 | 35,696,459.01 | 125,165,831.6 |
| 管理费用 | 48,366,970.55 | 35,047,385.86 | 12,402,068.5 | 65,148,310.46 |
| 研发费用 | 21,816,849.53 | 14,480,935.62 | 7,340,182.16 | 38,968,076.78 |
| 财务费用 | 1,721,067.62 | 1,094,440.72 | 616,896.38 | 1,604,301.49 |
| 其中:利息费用 | 1,772,810.52 | 1,184,276.2 | 590,558.82 | 1,977,382.85 |
| 其中:利息收入 | 36,192.62 | 26,082.23 | 13,705.25 | 80,457.03 |
| 加:公允价值变动收益 | -24,899.9 | -15,379.35 | -8,055.85 | -65,179.15 |
| 加:投资收益 | -290,254.64 | -261,187.55 | -218,024.9 | -195,988.6 |
| 净敞口套期收益 | 0 | 0 | 0 | - |
| 汇兑收益 | 0 | 0 | 0 | - |
| 资产处置收益 | 0 | 0 | 0 | - |
| 资产减值损失(新) | -5,500,447.71 | -5,500,447.71 | 0 | -7,178,299.19 |
| 信用减值损失(新) | -4,712,708.92 | -4,303,996.18 | -4,805,169.97 | -6,112,747.69 |
| 其他收益 | 19,929.38 | 19,679 | 529,552.89 | 463,314.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -46,327,062.16 | -40,937,220.53 | -21,889,366.63 | -54,157,365.4 |
| 加:营业外收入 | 482,001.89 | 457,236.89 | 21.3 | 565,563.01 |
| 减:营业外支出 | 187,881.26 | 187,081.26 | 0 | 14,579.35 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -46,032,941.53 | -40,667,064.9 | -21,889,345.33 | -53,606,381.74 |
| 减:所得税费用 | 23,989.28 | -546,964.02 | -767,137.38 | -325,364.86 |
| 六、净利润 | -46,056,930.81 | -40,120,100.88 | -21,122,207.95 | -53,281,016.88 |
| 持续经营净利润 | -46,056,930.81 | -40,120,100.88 | -21,122,207.95 | -53,281,016.88 |
| 终止经营净利润 | 0 | 0 | 0 | - |
| 归属于母公司股东的净利润 | -43,317,478.14 | -37,775,397.48 | -18,959,108.45 | -48,792,770.94 |
| 少数股东损益 | -2,739,452.67 | -2,344,703.4 | -2,163,099.5 | -4,488,245.94 |
| (一)基本每股收益 | -0.04 | -0.04 | -0.02 | -0.05 |
| (二)稀释每股收益 | -0.04 | -0.04 | -0.02 | -0.05 |
| 八、其他综合收益 | 0 | 0 | - | - |
| 归属于母公司股东的其他综合收益 | 0 | 0 | - | - |
| 九、综合收益总额 | -46,056,930.81 | -40,120,100.88 | -21,122,207.95 | -53,281,016.88 |
| 归属于母公司股东的综合收益总额 | -43,317,478.14 | -37,775,397.48 | -18,959,108.45 | -48,792,770.94 |
| 归属于少数股东的综合收益总额 | -2,739,452.67 | -2,344,703.4 | -2,163,099.5 | -4,488,245.94 |
| 公告日期 | 2023-10-27 | 2023-08-23 | 2023-04-29 | 2023-04-27 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |